The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 136,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Cell & gene therapy in pharma: recombinant viral vectors. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s Technology Foresights, which uses over 730,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
Recombinant viral vectors is a key innovation area in the cell & gene therapy
Recombinant viral vectors are efficient vehicles with the ability to deliver a gene of choice to target cells/tissue. Viral vectors are derived from different viruses and as such are characterized by different features. These vectors play a fundamental role in molecular biology research and are applicable in the field of gene therapy and vaccine development.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 375+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of recombinant viral vector-based medicinal preparations.
Key players in recombinant viral vectors – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to recombinant viral vectors
Source: GlobalData Patent Analytics
Merck is one of the leading patent filers in recombinant viral vector-based medicinal preparations. It is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. V-184, Lassa fever vaccine, LV-305, and MV-ZIKA are some of the recombinant vector vaccines, which are in clinical stages of development by Merck. Other leading patent filers in recombinant viral vectors include C. H. Boehringer Sohn and Bavarian Nordic.
In terms of application diversity, Mayo Clinic is the top company, followed by Mount Sinai Health and Erasmus MC.
By means of geographic reach, Vaxart holds the top position, Otsuka and American Gene Technologies are in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
